Low GLP1 Therapy Maintains Weight, Body Composition, & Metabolic Improvements

A study of users of semaglutide and tirzepatide found that every other week dosing at their current dose led to weight loss maintenance (and slight weight loss) over 36 weeks.

Methods: This retrospective case series included 30 adults who achieved weight plateau while on weekly semaglutide or tirzepatide. Patients transitioned to reduced-frequency dosing (usually every other week) at their existing dose.

Results: Patients maintained reduced-frequency dosing for an average of 36.3 weeks. Weight decreased from 87.9 ± 2.4 kg at pre-treatment to 74.1 ± 2.4 kg at plateau and further to 72.4 ± 2.2 kg on maintenance dosing (p < 0.01). Total body and truncal fat declined, while skeletal muscle mass stabilized on the reduced-frequency regimen. Metabolic parameters improved during weekly dosing and these gains were maintained during reduced-frequency therapy.

Conclusions: In patients with prior weight loss and metabolic improvement on GLP1 therapy, reduced-frequency maintenance dosing preserved outcomes.

I have no objections to the drug, but it’s also been well-established and well documented that you can achieve all these effects and results with a ketogenic (or similar) diet.

This will pair nicely with recently deployed oral protocols.

connect to